Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?
Bourque JM, Velazquez EJ, Borges-Neto S, Shaw LK, Whellan DJ, O’Connor C. Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? American Heart Journal 2003, 145: 758-767. PMID: 12766731, DOI: 10.1016/s0002-8703(02)94818-0.Peer-Reviewed Original ResearchMeSH KeywordsCoronary DiseaseFemaleFluorodeoxyglucose F18Heart FailureHumansMaleMyocardial RevascularizationProspective StudiesRadiopharmaceuticalsRetrospective StudiesSurvival RateThallium RadioisotopesTomography, Emission-ComputedTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsSignificant coronary artery diseaseCoronary artery diseaseLong-term mortalityArtery diseaseSurvival rateHeart failureTreatment strategiesImpaired left ventricular functionLong-term mortality ratesIschemic heart failureLeft ventricular functionIntermediate survival ratesNuclear imaging studiesLack of randomizationLower survival rateEjection fractionVentricular functionViable myocardiumReferral biasStudy protocolTreatment allocationLarge cohortPrognostic studiesMortality ratePatients